Projects overview

Sort by


Toggle all information

EBODAC | Communication strategy and tools for optimizing the impact of Ebola vaccination deployment – Sofia ref.: 115847

01-12-2014

-

30-11-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2014-02-single-stage
IMI2-2014-02-04 Deployment and compliance of vaccination regimens

ADAPTED | Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975

01-10-2016

-

30-09-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-06 From ApoE biology to validated Alzheimer’s disease targets

NGN-PET | Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

01-04-2017

-

31-03-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-03 PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN

COMBACTE-CDI | Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

01-11-2017

-

30-04-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-01 ADDRESSING THE CLINICAL BURDEN OF CLOSTRIDIUM DIFFICILE INFECTION (CDI): EVALUATION OF THE BURDEN, CURRENT PRACTICES AND SET-UP OF A EUROPEAN RESEARCH PLATFORM (PART OF THE IMI NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME)

RHAPSODY | Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881

01-04-2016

-

30-09-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-03-two-stage
IMI2-2015-03-02 Assessing Risk and Progression of Prediabetes and Type 2 Diabetes to Enable Disease Modification

ROADMAP | Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020

01-11-2016

-

31-10-2018

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-06-two-stage
IMI2-2015-06-03 Real World Outcomes Across the AD Spectrum (ROADS) to Better Care

ITCC-P4 | ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

01-01-2017

-

31-12-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER

MOBILISE-D | Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

01-04-2019

-

30-06-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-07 Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice

WEB-RADR 2 | WEB-RADR 2

01-09-2018

-

30-06-2020

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-11-single-stage
IMI2-2017-11-01 Exploitation of IMI project results

DO-IT | Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055

01-02-2017

-

31-01-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-06 COORDINATION AND SUPPORT ACTIONS (CSA) FOR THE BIG DATA FOR BETTER OUTCOMES PROGRAMME

RespiriNTM | Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

01-05-2019

-

30-04-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-16-single-stage
IMI2-2018-16-02 Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs

NEURONET | Efficiently Networking European Neurodegeneration Research

01-03-2019

-

31-08-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-05 Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative

BIGPICTURE | Central Repository for Digital Pathology

01-02-2021

-

31-01-2027

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2019-18-two-stage
IMI2-2019-18-01 Central repository of digital pathology slides to support the development of artificial intelligence tools

PIONEER | Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope

01-05-2018

-

31-10-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-10-two-stage
IMI2-2016-10-02 How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer

MACUSTAR | Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076

01-09-2017

-

31-05-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-07-two-stage
IMI2-2015-07-04 DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION

PD-MitoQUANT | PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

01-02-2019

-

31-07-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-13-two-stage
IMI2-2017-13-04 Mitochondrial Dysfunction in Neurodegeneration

PharmaLedger | PharmaLedger

01-01-2020

-

31-12-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-02 Blockchain Enabled Healthcare

EU-PEARL | EU Patient- cEntric clinicAl tRial pLatform

01-11-2019

-

30-04-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-01 Integrated research platforms enabling patient-centric drug development

AMYPAD | Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952

01-10-2016

-

30-09-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-05-two-stage
IMI2-2015-05-04 Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)

RTCure | Rheuma Tolerance for Cure

01-09-2017

-

31-08-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2016-09-two-stage
IMI2-2016-09-02 DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES

GetReal Initiative | The GetReal Initiative

01-06-2018

-

30-04-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2017-11-single-stage
IMI2-2017-11-01 Exploitation of IMI project results

INNODIA HARVEST | Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA

01-05-2020

-

30-04-2024

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2019-19-single-stage
IMI2-2019-19-01 Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities

imSAVAR | Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies

01-12-2019

-

30-11-2025

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-15-two-stage
IMI2-2018-15-04 Emerging translational safety technologies and tools for interrogating human immuno-biology

AB-DiRecT | Antibiotic Distribution and Recovery in Tissue

01-07-2019

-

30-09-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2018-16-single-stage
IMI2-2018-16-04 Determination of gepotidacin levels in tonsils and prostatic tissue
Powered by Chris Decubber BV